{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:43:13Z","timestamp":1790678593527,"version":"4.1.0"},"reference-count":105,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Targeted therapies against the BCR-ABL1 kinase have revolutionized treatment of chronic phase (CP) chronic myeloid leukemia (CML). In contrast, management of blast crisis (BC) CML remains challenging because BC cells acquire complex molecular alterations that confer stemness features to progenitor populations and resistance to BCR-ABL1 tyrosine kinase inhibitors. Comprehensive models of BC transformation have proved elusive because of the rarity and genetic heterogeneity of BC, but are important for developing biomarkers predicting BC progression and effective therapies. To better understand BC, we performed an integrated multiomics analysis of 74 CP and BC samples using whole-genome and exome sequencing, transcriptome and methylome profiling, and chromatin immunoprecipitation followed by high-throughput sequencing. Employing pathway-based analysis, we found the BC genome was significantly enriched for mutations affecting components of the polycomb repressive complex (PRC) pathway. While transcriptomically, BC progenitors were enriched and depleted for PRC1- and PRC2-related gene sets respectively. By integrating our data sets, we determined that BC progenitors undergo PRC-driven epigenetic reprogramming toward a convergent transcriptomic state. Specifically, PRC2 directs BC DNA hypermethylation, which in turn silences key genes involved in myeloid differentiation and tumor suppressor function via so-called epigenetic switching, whereas PRC1 represses an overlapping and distinct set of genes, including novel BC tumor suppressors. On the basis of these observations, we developed an integrated model of BC that facilitated the identification of combinatorial therapies capable of reversing BC reprogramming (decitabine+PRC1 inhibitors), novel PRC-silenced tumor suppressor genes (NR4A2), and gene expression signatures predictive of disease progression and drug resistance in CP.<\/jats:p>","DOI":"10.1182\/blood.2020004834","type":"journal-article","created":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T22:00:00Z","timestamp":1583877600000},"page":"2337-2353","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":68,"title":["An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia"],"prefix":"10.1182","volume":"135","author":[{"given":"Tun Kiat","family":"Ko","sequence":"first","affiliation":[{"name":"Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6945-9624","authenticated-orcid":false,"given":"Asif","family":"Javed","sequence":"first","affiliation":[{"name":"Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;"},{"name":"School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0443-2746","authenticated-orcid":false,"given":"Kian Leong","family":"Lee","sequence":"first","affiliation":[{"name":"Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thushangi N.","family":"Pathiraja","sequence":"first","affiliation":[{"name":"Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingliang","family":"Liu","sequence":"first","affiliation":[{"name":"Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeen","family":"Malik","sequence":"first","affiliation":[{"name":"Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila Xinxuan","family":"Soh","sequence":"first","affiliation":[{"name":"Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu Ting","family":"Heng","sequence":"first","affiliation":[{"name":"Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-3787","authenticated-orcid":false,"given":"Naoto","family":"Takahashi","sequence":"first","affiliation":[{"name":"Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna H. J.","family":"Tan","sequence":"first","affiliation":[{"name":"Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Bhatia","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, University of Alabama Birmingham, Birmingham, AL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis J.","family":"Khng","sequence":"first","affiliation":[{"name":"Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee-Joo","family":"Chng","sequence":"first","affiliation":[{"name":"Department of Hematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore;"},{"name":"Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore;"},{"name":"Cancer Science Institute of Singapore, National University of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee Yen","family":"Sia","sequence":"first","affiliation":[{"name":"Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1796-5162","authenticated-orcid":false,"given":"David A.","family":"Fruman","sequence":"first","affiliation":[{"name":"Department of Molecular Biology & Biochemistry, University of California, Irvine, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"King Pan","family":"Ng","sequence":"first","affiliation":[{"name":"Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu En","family":"Chan","sequence":"first","affiliation":[{"name":"Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Jiajing","family":"Xie","sequence":"first","affiliation":[{"name":"Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiangze","family":"Hoi","sequence":"first","affiliation":[{"name":"Computational and Systems Biology, Genome Institute of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl Xueli","family":"Chan","sequence":"first","affiliation":[{"name":"Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey S. M.","family":"Teo","sequence":"first","affiliation":[{"name":"Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9811-6180","authenticated-orcid":false,"given":"Oscar","family":"Velazquez Camacho","sequence":"first","affiliation":[{"name":"Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Yang","family":"Meah","sequence":"first","affiliation":[{"name":"Human Genetics, Genome Institute of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiea Chuen","family":"Khor","sequence":"first","affiliation":[{"name":"Human Genetics, Genome Institute of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin Thing J.","family":"Ong","sequence":"first","affiliation":[{"name":"Next Generation Sequencing Platform, Genome Institute of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Jia W.","family":"Soon","sequence":"first","affiliation":[{"name":"Next Generation Sequencing Platform, Genome Institute of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0179-8048","authenticated-orcid":false,"given":"Patrick","family":"Tan","sequence":"first","affiliation":[{"name":"Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore;"},{"name":"Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline C.","family":"Ng","sequence":"first","affiliation":[{"name":"Computational and Systems Biology, Genome Institute of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Chuah","sequence":"first","affiliation":[{"name":"Department of Haematology, Singapore General Hospital, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3381-7266","authenticated-orcid":false,"given":"Axel M.","family":"Hillmer","sequence":"first","affiliation":[{"name":"Cancer Therapeutics & Stratified Oncology, Genome Institute of Singapore, Singapore;"},{"name":"Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9460-3483","authenticated-orcid":false,"given":"S. Tiong","family":"Ong","sequence":"first","affiliation":[{"name":"Cancer & Stem Cell Biology Signature Research Programme, Duke-NUS Medical School, Singapore;"},{"name":"Department of Haematology, Singapore General Hospital, Singapore;"},{"name":"Department of Medical Oncology, National Cancer Centre, Singapore; and"},{"name":"Department of Medicine, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2020062511295764200_B1","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"issue":"24","key":"2020062511295764200_B2","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020062511295764200_B3","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J Clin Invest"},{"issue":"9","key":"2020062511295764200_B4","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2020062511295764200_B5","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution: past, present, and the future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"issue":"5","key":"2020062511295764200_B6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ccell.2018.03.025","article-title":"A convergence-based framework for cancer drug resistance","volume":"33","author":"Konieczkowski","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"2020062511295764200_B7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/molbev\/msv212","article-title":"The convergent cancer evolution toward a single cellular destination","volume":"33","author":"Chen","year":"2016","journal-title":"Mol Biol Evol"},{"issue":"11","key":"2020062511295764200_B8","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41568-018-0056-x","article-title":"Stem cell fate in cancer growth, progression and therapy resistance","volume":"18","author":"Lytle","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2020062511295764200_B9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"issue":"25","key":"2020062511295764200_B10","doi-asserted-by":"crossref","first-page":"E2298","DOI":"10.1073\/pnas.1301838110","article-title":"Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function","volume":"110","author":"Lim","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"2020062511295764200_B11","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2020062511295764200_B12","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.leu.2404227","article-title":"Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis","volume":"20","author":"Zheng","year":"2006","journal-title":"Leukemia"},{"key":"2020062511295764200_B13","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.semcancer.2017.07.006","article-title":"Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options","volume":"51","author":"Koschmieder","year":"2018","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"2020062511295764200_B14","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Cancer Discov"},{"issue":"11","key":"2020062511295764200_B15","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-15-1439","article-title":"Chronic myelogenous leukemia- initiating cells require polycomb group protein EZH2","volume":"6","author":"Xie","year":"2016","journal-title":"Cancer Discov"},{"issue":"1","key":"2020062511295764200_B16","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood-2006-12-065599","article-title":"The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia","volume":"110","author":"Mohty","year":"2007","journal-title":"Blood"},{"issue":"22","key":"2020062511295764200_B17","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1182\/blood-2010-02-270660","article-title":"BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells","volume":"116","author":"Rizo","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2020062511295764200_B18","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2011-06-359232","article-title":"Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells","volume":"119","author":"Sengupta","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2020062511295764200_B19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1083\/jcb.201808028","article-title":"Polycomb complexes in normal and malignant hematopoiesis","volume":"218","author":"Di Carlo","year":"2019","journal-title":"J Cell Biol"},{"issue":"1","key":"2020062511295764200_B20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cell.2017.08.002","article-title":"Genome regulation by polycomb and trithorax: 70 years and counting","volume":"171","author":"Schuettengruber","year":"2017","journal-title":"Cell"},{"issue":"11","key":"2020062511295764200_B21","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nrc1991","article-title":"Polycomb silencers control cell fate, development and cancer","volume":"6","author":"Sparmann","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"2020062511295764200_B22","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/onc.2015.195","article-title":"Context-dependent actions of Polycomb repressors in cancer","volume":"35","author":"Koppens","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"2020062511295764200_B23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2017-02-739490","article-title":"Polycomb repressive complexes in hematological malignancies","volume":"130","author":"Iwama","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2020062511295764200_B24","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1084\/jem.20181276","article-title":"Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML","volume":"216","author":"Basheer","year":"2019","journal-title":"J Exp Med"},{"issue":"2","key":"2020062511295764200_B25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat Med"},{"issue":"7463","key":"2020062511295764200_B26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer [published correction appears in Nature. 2013;502(7470):258]","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"19","key":"2020062511295764200_B27","doi-asserted-by":"crossref","first-page":"7411","DOI":"10.1158\/0008-5472.CAN-10-1438","article-title":"Activation-induced cytidine deaminase accelerates clonal evolution in BCR-ABL1-driven B-cell lineage acute lymphoblastic leukemia","volume":"70","author":"Gruber","year":"2010","journal-title":"Cancer Res"},{"issue":"5","key":"2020062511295764200_B28","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1084\/jem.20062662","article-title":"Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells","volume":"204","author":"Feldhahn","year":"2007","journal-title":"J Exp Med"},{"issue":"7457","key":"2020062511295764200_B29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"issue":"8","key":"2020062511295764200_B30","first-page":"1798","article-title":"Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins","volume":"63","author":"Brady","year":"2003","journal-title":"Cancer Res"},{"issue":"10","key":"2020062511295764200_B31","first-page":"2791","article-title":"Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70\/86 heterodimer","volume":"62","author":"Gaymes","year":"2002","journal-title":"Cancer Res"},{"issue":"4","key":"2020062511295764200_B32","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol"},{"issue":"1","key":"2020062511295764200_B33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-2164-11-41","article-title":"Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia","volume":"11","author":"Nacheva","year":"2010","journal-title":"BMC Genomics"},{"key":"2020062511295764200_B34","doi-asserted-by":"crossref","first-page":"bav006","DOI":"10.1093\/database\/bav006","article-title":"PathCards: multi-source consolidation of human biological pathways","volume":"2015","author":"Belinky","year":"2015","journal-title":"Database (Oxford)"},{"issue":"2","key":"2020062511295764200_B35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.stem.2011.12.017","article-title":"Polycomb associates genome-wide with a specific RNA polymerase II variant, and regulates metabolic genes in ESCs","volume":"10","author":"Brookes","year":"2012","journal-title":"Cell Stem Cell"},{"issue":"5","key":"2020062511295764200_B36","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/ng.127","article-title":"An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors","volume":"40","author":"Ben-Porath","year":"2008","journal-title":"Nat Genet"},{"issue":"9","key":"2020062511295764200_B37","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm.2415","article-title":"Stem cell gene expression programs influence clinical outcome in human leukemia","volume":"17","author":"Eppert","year":"2011","journal-title":"Nat Med"},{"issue":"2","key":"2020062511295764200_B38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrg3607","article-title":"Chromatin modifiers and remodellers: regulators of cellular differentiation","volume":"15","author":"Chen","year":"2014","journal-title":"Nat Rev Genet"},{"issue":"6","key":"2020062511295764200_B39","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.stem.2014.05.006","article-title":"Chromatin repressive complexes in stem cells, development, and cancer","volume":"14","author":"Laugesen","year":"2014","journal-title":"Cell Stem Cell"},{"issue":"10","key":"2020062511295764200_B40","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nrc2931","article-title":"Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins","volume":"10","author":"Mills","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2020062511295764200_B41","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.stem.2010.08.002","article-title":"Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer","volume":"7","author":"Sauvageau","year":"2010","journal-title":"Cell Stem Cell"},{"issue":"5600","key":"2020062511295764200_B42","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"issue":"1","key":"2020062511295764200_B43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3727\/096504013X13786659070271","article-title":"Restoration of INK4a\/ARF gene inhibits cell growth and cooperates with imatinib mesylate in Philadelphia chromosome-positive leukemias","volume":"21","author":"Bai","year":"2013","journal-title":"Oncol Res"},{"issue":"5195","key":"2020062511295764200_B44","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1126\/science.7809631","article-title":"Inhibition of ras-induced proliferation and cellular transformation by p16INK4","volume":"267","author":"Serrano","year":"1995","journal-title":"Science"},{"issue":"6","key":"2020062511295764200_B45","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2010.63","article-title":"Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia","volume":"24","author":"Virely","year":"2010","journal-title":"Leukemia"},{"issue":"23","key":"2020062511295764200_B46","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1182\/blood-2015-02-626127","article-title":"PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia","volume":"125","author":"Dang","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2020062511295764200_B47","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2011-08-370981","article-title":"Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia","volume":"119","author":"Zhao","year":"2012","journal-title":"Blood"},{"issue":"7191","key":"2020062511295764200_B48","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"issue":"3","key":"2020062511295764200_B49","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2014-06-581173","article-title":"Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression","volume":"125","author":"Beer","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2020062511295764200_B50","doi-asserted-by":"crossref","first-page":"e74864","DOI":"10.1371\/journal.pone.0074864","article-title":"Functionally deregulated AML1\/RUNX1 cooperates with BCR-ABL to induce a blastic phase-like phenotype of chronic myelogenous leukemia in mice","volume":"8","author":"Yamamoto","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"2020062511295764200_B51","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","article-title":"How I treat CML blast crisis","volume":"120","author":"Hehlmann","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2020062511295764200_B52","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"issue":"6","key":"2020062511295764200_B53","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nm.4336","article-title":"Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia","volume":"23","author":"Giustacchini","year":"2017","journal-title":"Nat Med"},{"issue":"18","key":"2020062511295764200_B54","first-page":"5716","article-title":"Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin","volume":"63","author":"Ly","year":"2003","journal-title":"Cancer Res"},{"issue":"24","key":"2020062511295764200_B55","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1001\/jama.2010.1862","article-title":"Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia","volume":"304","author":"Gentles","year":"2010","journal-title":"JAMA"},{"issue":"13","key":"2020062511295764200_B56","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1158\/0008-5472.CAN-03-3247","article-title":"Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells","volume":"64","author":"Georgantas","year":"2004","journal-title":"Cancer Res"},{"issue":"8","key":"2020062511295764200_B57","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"issue":"8","key":"2020062511295764200_B58","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","article-title":"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes","volume":"42","author":"Nikoloski","year":"2010","journal-title":"Nat Genet"},{"issue":"19","key":"2020062511295764200_B59","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"issue":"17","key":"2020062511295764200_B60","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2005.11.981","article-title":"Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate","volume":"23","author":"Issa","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020062511295764200_B61","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/cncr.11543","article-title":"Results of decitabine (5-aza-2\u2019deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"issue":"10","key":"2020062511295764200_B62","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/sj.leu.2400796","article-title":"Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia","volume":"11","author":"Kantarjian","year":"1997","journal-title":"Leukemia"},{"issue":"9","key":"2020062511295764200_B63","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2016.143","article-title":"Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia","volume":"30","author":"Heller","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"2020062511295764200_B64","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood.V94.7.2452.419k23_2452_2460","article-title":"ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia","volume":"94","author":"Asimakopoulos","year":"1999","journal-title":"Blood"},{"issue":"7","key":"2020062511295764200_B65","doi-asserted-by":"crossref","first-page":"e22110","DOI":"10.1371\/journal.pone.0022110","article-title":"Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia","volume":"6","author":"Jelinek","year":"2011","journal-title":"PLoS One"},{"issue":"10","key":"2020062511295764200_B66","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nrc3130","article-title":"A decade of exploring the cancer epigenome - biological and translational implications","volume":"11","author":"Baylin","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"7303","key":"2020062511295764200_B67","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature09165","article-title":"Conserved role of intragenic DNA methylation in regulating alternative promoters","volume":"466","author":"Maunakea","year":"2010","journal-title":"Nature"},{"issue":"3","key":"2020062511295764200_B68","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1101\/gr.147942.112","article-title":"Dynamic DNA methylation across diverse human cell lines and tissues","volume":"23","author":"Varley","year":"2013","journal-title":"Genome Res"},{"issue":"3","key":"2020062511295764200_B69","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ccr.2011.12.029","article-title":"Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells","volume":"21","author":"Tsai","year":"2012","journal-title":"Cancer Cell"},{"issue":"2","key":"2020062511295764200_B70","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1634\/stemcells.19-2-125","article-title":"The role of C\/EBP(epsilon) in the terminal stages of granulocyte differentiation","volume":"19","author":"Lekstrom-Himes","year":"2001","journal-title":"Stem Cells"},{"issue":"2","key":"2020062511295764200_B71","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood.V84.2.446.446","article-title":"Myeloid differentiation mediated through retinoic acid receptor\/retinoic X receptor (RXR) not RXR\/RXR pathway","volume":"84","author":"Dawson","year":"1994","journal-title":"Blood"},{"issue":"4","key":"2020062511295764200_B72","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.molimm.2010.10.016","article-title":"CLEC5A (MDL-1) is a novel PU.1 transcriptional target during myeloid differentiation","volume":"48","author":"Batliner","year":"2011","journal-title":"Mol Immunol"},{"issue":"2","key":"2020062511295764200_B73","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1600-0609.1988.tb00805.x","article-title":"Biosynthesis and processing of myeloperoxidase--a marker for myeloid cell differentiation","volume":"40","author":"Nauseef","year":"1988","journal-title":"Eur J Haematol"},{"issue":"6 Pt 2","key":"2020062511295764200_B74","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/0091-6749(94)90328-X","article-title":"Distinguishing features of basophil and neutrophil activation by major basic protein","volume":"94","author":"Thomas","year":"1994","journal-title":"J Allergy Clin Immunol"},{"issue":"24","key":"2020062511295764200_B75","doi-asserted-by":"crossref","first-page":"21960","DOI":"10.1074\/jbc.M007997200","article-title":"Subcellular distribution and cytokine- and chemokine-regulated secretion of leukolysin\/MT6-MMP\/MMP-25 in neutrophils","volume":"276","author":"Kang","year":"2001","journal-title":"J Biol Chem"},{"issue":"52","key":"2020062511295764200_B76","doi-asserted-by":"crossref","first-page":"51068","DOI":"10.1074\/jbc.M205121200","article-title":"The link module from human TSG-6 inhibits neutrophil migration in a hyaluronan- and inter-alpha -inhibitor-independent manner","volume":"277","author":"Getting","year":"2002","journal-title":"J Biol Chem"},{"issue":"21","key":"2020062511295764200_B77","first-page":"10132","article-title":"Interdependence of PRC1 and PRC2 for recruitment to Polycomb Response Elements","volume":"44","author":"Kahn","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2020062511295764200_B78","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nm.3418","article-title":"Self-renewal as a therapeutic target in human colorectal cancer","volume":"20","author":"Kreso","year":"2014","journal-title":"Nat Med"},{"issue":"7427","key":"2020062511295764200_B79","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"issue":"350","key":"2020062511295764200_B80","doi-asserted-by":"crossref","first-page":"350ra104","DOI":"10.1126\/scitranslmed.aad6066","article-title":"Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBP\u03b1 expression","volume":"8","author":"Yong","year":"2016","journal-title":"Sci Transl Med"},{"issue":"5","key":"2020062511295764200_B81","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccr.2013.03.030","article-title":"In vivo RNAi screen for BMI1 targets identifies TGF-\u03b2\/BMP-ER stress pathways as key regulators of neural- and malignant glioma-stem cell homeostasis","volume":"23","author":"Gargiulo","year":"2013","journal-title":"Cancer Cell"},{"issue":"13","key":"2020062511295764200_B82","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1128\/MCB.02244-06","article-title":"Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis","volume":"27","author":"Wiederschain","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"9","key":"2020062511295764200_B83","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1101\/gad.381706","article-title":"Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions","volume":"20","author":"Bracken","year":"2006","journal-title":"Genes Dev"},{"issue":"2","key":"2020062511295764200_B84","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/ng1972","article-title":"A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing","volume":"39","author":"Ohm","year":"2007","journal-title":"Nat Genet"},{"issue":"2","key":"2020062511295764200_B85","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/ng1941","article-title":"Epigenetic stem cell signature in cancer","volume":"39","author":"Widschwendter","year":"2007","journal-title":"Nat Genet"},{"issue":"2","key":"2020062511295764200_B86","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/ng1950","article-title":"Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer","volume":"39","author":"Schlesinger","year":"2007","journal-title":"Nat Genet"},{"issue":"7078","key":"2020062511295764200_B87","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nature04431","article-title":"The Polycomb group protein EZH2 directly controls DNA methylation [published correction appears in Nature. 2007;446(7137):824]","volume":"439","author":"Vir\u00e9","year":"2006","journal-title":"Nature"},{"issue":"3","key":"2020062511295764200_B88","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ccell.2017.08.006","article-title":"Chronic cigarette smoke-induced epigenomic changes precede sensitization of bronchial epithelial cells to single-step transformation by KRAS mutations","volume":"32","author":"Vaz","year":"2017","journal-title":"Cancer Cell"},{"issue":"5","key":"2020062511295764200_B89","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/ncb1403","article-title":"Chromatin signatures of pluripotent cell lines","volume":"8","author":"Azuara","year":"2006","journal-title":"Nat Cell Biol"},{"issue":"2","key":"2020062511295764200_B90","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cell.2006.02.041","article-title":"A bivalent chromatin structure marks key developmental genes in embryonic stem cells","volume":"125","author":"Bernstein","year":"2006","journal-title":"Cell"},{"issue":"6","key":"2020062511295764200_B91","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ccr.2004.10.015","article-title":"MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors","volume":"6","author":"Huntly","year":"2004","journal-title":"Cancer Cell"},{"issue":"14","key":"2020062511295764200_B92","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2017-05-783845","article-title":"hsa-mir183\/EGR1-mediated regulation of E2F1 is required for CML stem\/progenitor cell survival","volume":"131","author":"Pellicano","year":"2018","journal-title":"Blood"},{"issue":"41","key":"2020062511295764200_B93","doi-asserted-by":"crossref","first-page":"69281","DOI":"10.18632\/oncotarget.20612","article-title":"Loss of Egr1, a human del5q gene, accelerates BCR-ABL driven chronic myelogenous leukemia","volume":"8","author":"Maifrede","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2020062511295764200_B94","doi-asserted-by":"crossref","first-page":"e002","DOI":"10.1621\/nrs.04002","article-title":"The NR4A subgroup: immediate early response genes with pleiotropic physiological roles","volume":"4","author":"Maxwell","year":"2006","journal-title":"Nucl Recept Signal"},{"issue":"6","key":"2020062511295764200_B95","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1210\/me.2003-0247","article-title":"Regulation of the osteopontin gene by the orphan nuclear receptor NURR1 in osteoblasts","volume":"18","author":"Lammi","year":"2004","journal-title":"Mol Endocrinol"},{"issue":"2","key":"2020062511295764200_B96","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","article-title":"A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib","volume":"115","author":"McWeeney","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2020062511295764200_B97","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2005-05-2155","article-title":"Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML","volume":"107","author":"Yong","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2020062511295764200_B98","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2014-10-606822","article-title":"Polycomb genes, miRNA, and their deregulation in B-cell malignancies","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2020062511295764200_B99","doi-asserted-by":"crossref","first-page":"7091","DOI":"10.1038\/ncomms8091","article-title":"Dissecting the role of aberrant DNA methylation in human leukaemia","volume":"6","author":"Amabile","year":"2015","journal-title":"Nat Commun"},{"issue":"1","key":"2020062511295764200_B100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/carcin\/bgp220","article-title":"Epigenetics in cancer","volume":"31","author":"Sharma","year":"2010","journal-title":"Carcinogenesis"},{"issue":"12","key":"2020062511295764200_B101","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/ncb2125","article-title":"The orphan nuclear receptor Nurr1 restricts the proliferation of haematopoietic stem cells","volume":"12","author":"Sirin","year":"2010","journal-title":"Nat Cell Biol"},{"issue":"6","key":"2020062511295764200_B102","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nm1579","article-title":"Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia","volume":"13","author":"Mullican","year":"2007","journal-title":"Nat Med"},{"issue":"9","key":"2020062511295764200_B103","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1182\/blood-2010-02-267906","article-title":"Reduced NR4A gene dosage leads to mixed myelodysplastic\/myeloproliferative neoplasms in mice","volume":"117","author":"Ramirez-Herrick","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2020062511295764200_B104","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2017-07-795757","article-title":"NR4A1 and NR4A3 restrict HSC proliferation via reciprocal regulation of C\/EBP\u03b1 and inflammatory signaling","volume":"131","author":"Freire","year":"2018","journal-title":"Blood"},{"issue":"15_suppl","key":"2020062511295764200_B105","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1200\/JCO.2017.35.15_suppl.2574","article-title":"Phase 1 results of PTC596, a novel small molecule targeting cancer stem cells (CSCs) by reducing levels of BMI1 protein","volume":"35","author":"Infante","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/26\/2337\/1745470\/bloodbld2020004834.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/26\/2337\/1745470\/bloodbld2020004834.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T11:31:20Z","timestamp":1593084680000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/26\/2337\/452673\/An-integrative-model-of-pathway-convergence-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":105,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2020,6,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020004834","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737536007.793577229","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,25]]}}}